Neurotrope (NTRP) Now Covered By Maxim Group with $16.0000 Target; Last Week Seattle Genetics, Inc. (SGEN) Coverage

Neurotrope, Inc. (NASDAQ:NTRP) Logo

Among 18 analysts covering Seattle Genetics (NASDAQ:SGEN), 9 have Buy rating, 0 Sell and 9 Hold. Therefore 50% are positive. Seattle Genetics had 67 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was maintained by William Blair on Tuesday, August 25 with “Buy”. On Friday, October 27 the stock rating was maintained by RBC Capital Markets with “Buy”. The firm has “Outperform” rating given on Friday, August 14 by Leerink Swann. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Neutral” rating by Bank of America on Wednesday, February 7. Oppenheimer initiated the stock with “Hold” rating in Wednesday, November 8 report. The firm earned “Overweight” rating on Wednesday, March 21 by Morgan Stanley. The company was maintained on Monday, June 26 by Oppenheimer. Barclays Capital maintained Seattle Genetics, Inc. (NASDAQ:SGEN) on Monday, October 16 with “Equal-Weight” rating. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Hold” rating given on Monday, June 19 by Cowen & Co. Barclays Capital maintained Seattle Genetics, Inc. (NASDAQ:SGEN) on Wednesday, July 27 with “Overweight” rating. See Seattle Genetics, Inc. (NASDAQ:SGEN) latest ratings:

27/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $77.0000 Maintain
21/03/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $69 New Target: $67 Maintain
20/03/2018 Broker: RBC Capital Markets Rating: Buy New Target: $73.0 Maintain
14/02/2018 Broker: J.P. Morgan Rating: Buy New Target: $66.0 Upgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Old Target: $60 Upgrade
07/02/2018 Broker: Needham Rating: Buy New Target: $74.0 Maintain
07/02/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $70 New Target: $68 Maintain
07/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $77.0 Maintain
07/02/2018 Broker: SunTrust Rating: Hold New Target: $60.0 Maintain
01/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $75.0 Maintain

Maxim Group issued a Buy rating on Neurotrope (NTRP). The firm has begun coverage on shares of NTRP in a a research report revealed on Wednesday, 16 May. Maxim Group’s price target gives upside of 78.77% from the company’s close price.

The stock decreased 1.00% or $0.09 during the last trading session, reaching $8.95. About 78,824 shares traded or 206.64% up from the average. Neurotrope, Inc. (NTRP) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Another recent and important Neurotrope, Inc. (NASDAQ:NTRP) news was published by which published an article titled: “Neurotrope, In Consultation With Leading Neuroscientists, Completes the Study Design for its Confirmatory Phase 2 …” on May 07, 2018.

Among 2 analysts covering Neurotrope (NTRP), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurotrope has $31 highest and $16 lowest target. $23.50’s average target is 162.57% above currents $8.95 stock price. Neurotrope had 2 analyst reports since April 12, 2017 according to SRatingsIntel.

Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease . The company has market cap of $70.77 million. The Company’s lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It currently has negative earnings. The firm also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C.

More recent Seattle Genetics, Inc. (NASDAQ:SGEN) news were published by: which released: “Seattle Genetics Fairly Valued, Pending Data” on May 14, 2018. Also published the news titled: “Seattle Genetics (SGEN) Q1 2018 Results – Earnings Call Transcript” on April 27, 2018.‘s news article titled: “Key events next week – healthcare” with publication date: April 27, 2018 was also an interesting one.

Since December 11, 2017, it had 3 insider buys, and 10 sales for $268.25 million activity. Shares for $24.57 million were bought by BAKER BROS. ADVISORS LP. 18,832 Seattle Genetics, Inc. (NASDAQ:SGEN) shares with value of $1.08M were sold by SIEGALL CLAY B. HIMES VAUGHN B sold $290,604 worth of stock. Another trade for 10,457 shares valued at $552,452 was made by DRACHMAN JONATHAN G on Monday, March 5. The insider Cline Darren S sold $497,983.

Investors sentiment increased to 1.23 in Q4 2017. Its up 0.45, from 0.78 in 2017Q3. It improved, as 24 investors sold Seattle Genetics, Inc. shares while 67 reduced holdings. 44 funds opened positions while 68 raised stakes. 141.83 million shares or 1.14% more from 140.23 million shares in 2017Q3 were reported. Daiwa Gru reported 3,250 shares or 0% of all its holdings. Bluecrest Mgmt invested in 6,280 shares or 0.01% of the stock. 5,901 were reported by Toronto Dominion Bancorporation. Voya Inv Management Limited Liability has 35,052 shares for 0% of their portfolio. Cwm Lc has 0% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 200 shares. Invsts invested in 0.32% or 5.22 million shares. Asset One Company Limited holds 203,907 shares. Jgp Gestao De Recursos Ltda accumulated 20,603 shares or 0.54% of the stock. Piedmont reported 0.01% stake. Dupont Capital reported 7,861 shares or 0.01% of all its holdings. Livforsakringsbolaget Skandia Omsesidigt reported 1,900 shares. Pathstone Family Office Limited Liability holds 330 shares. Sei Invs Communication reported 13,379 shares. Cornerstone Inc stated it has 0.01% in Seattle Genetics, Inc. (NASDAQ:SGEN). Strs Ohio reported 1,235 shares.

Seattle Genetics, Inc. (NASDAQ:SGEN) Institutional Positions Chart